人表皮生长因子受体2靶向[68Ga]Ga-ABY-025 PET/CT预测转移性乳腺癌早期代谢反应
这项单中心开放标签II期研究纳入40例HER2阳性乳腺癌患者(19例原发、21例转移),基线行[68Ga]Ga-ABY-025 PET/CT、[18F]F-FDG PET/CT及穿刺活检,2周期治疗后复查FDG PET/CT计算Δ-TLG。结果显示[68Ga]Ga-ABY-025 PET/CT的SUVmax截断值6.0可预测软组织病灶Δ-TLG低于-25%,灵敏度86%、特异度67%。
要点
- SUVmax截断值6.0预测软组织病灶Δ-TLG低于-25%的灵敏度86%、特异度67%,AUC 0.74。
- 该截断值与HER2状态比较,40例中12例出现临床相关的不一致结果。
- 原发乳腺癌代谢反应(-71%)较转移性乳腺癌(-27%)更明显。
核心结论
- [68Ga]Ga-ABY-025 PET/CT预测了HER2阳性乳腺癌对HER2靶向治疗的早期代谢反应。
- 复发疾病的代谢反应减弱。
- [68Ga]Ga-ABY-025 PET/CT似乎提供了靶向治疗诱导肿瘤代谢缓解所需的HER2表达估计,可能作为辅助诊断工具。
研究设计与样本
- 单中心开放标签II期研究,纳入40例已知HER2阳性的乳腺癌患者,其中原发乳腺癌19例、转移性乳腺癌21例(中位既往治疗3次)。
- 基线行[68Ga]Ga-ABY-025 PET/CT、[18F]F-FDG PET/CT及靶病灶粗针穿刺活检,2周期治疗后复查[18F]F-FDG PET/CT计算肿瘤病灶糖酵解的方向性变化(Δ-TLG)。
- 每例患者3次扫描均评估最大病灶(最多5个),采用受试者工作特征分析比较[68Ga]Ga-ABY-025 PET/CT的SUV与活检HER2状态及Δ-TLG。
主要发现
- 试验活检HER2阳性31例、HER2阴性6例、HER2临界阳性3例。
- [68Ga]Ga-ABY-025 PET/CT截断值SUVmax 6.0预测软组织病灶Δ-TLG低于-25%,灵敏度86%、特异度67%(AUC 0.74 [95%CI 0.67-0.82],P=0.01)。
- 与HER2状态比较,该截断值在40例中12例出现临床相关的不一致结果。
- 代谢反应(Δ-TLG)在原发乳腺癌为-71%(95%CI -58%至-83%,P<0.0001),较转移性乳腺癌的-27%(95%CI -16%至-38%,P<0.0001)更明显。
- [68Ga]Ga-ABY-025 SUVmax在原发乳腺癌为平均值9.8(95%CI 6.3-13.3),在转移性乳腺癌为13.9(95%CI 10.5-17.2),两组差异P=0.10。
关键数值与推荐
- [68Ga]Ga-ABY-025 PET/CT截断值SUVmax 6.0预测软组织病灶Δ-TLG低于-25%的灵敏度86%、特异度67%(AUC 0.74 [95%CI 0.67-0.82],P=0.01)。
- 试验活检HER2状态:阳性31例、阴性6例、临界阳性3例。
- 原发乳腺癌Δ-TLG为-71%(95%CI -58%至-83%,P<0.0001),转移性乳腺癌为-27%(95%CI -16%至-38%,P<0.0001)。
- 原发乳腺癌[68Ga]Ga-ABY-025 SUVmax平均值9.8(95%CI 6.3-13.3),转移性乳腺癌13.9(95%CI 10.5-17.2),P=0.10。
临床怎么用
- 原文结论为[68Ga]Ga-ABY-025 PET/CT预测了HER2阳性乳腺癌对HER2靶向治疗的早期代谢反应,可能作为辅助诊断工具。
- 原文未据此给出具体临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Imaging using the human epidermal growth factor receptor 2 (HER2)-binding tracer 68Ga-labeled ZHER2:2891-Cys-MMA-DOTA ([68Ga]Ga-ABY-025) was shown to reflect HER2 status determined by immunohistochemistry and in situ hybridization in metastatic breast cancer (MBC). This single-center open-label phase II study investigated how [68Ga]Ga-ABY-025 uptake corresponds to biopsy results and early treatment response in both primary breast cancer (PBC) planned for neoadjuvant chemotherapy and MBC. Methods: Forty patients with known positive HER2 status were included: 19 with PBC and 21 with MBC (median, 3 previous treatments). [68Ga]Ga-ABY-025 PET/CT, [18F]F-FDG PET/CT, and core-needle biopsies from targeted lesions were performed at baseline. [18F]F-FDG PET/CT was repeated after 2 cycles of therapy to calculate the directional change in tumor lesion glycolysis (Δ-TLG). The largest lesions (up to 5) were evaluated in all 3 scans per patient. SUVs from [68Ga]Ga-ABY-025 PET/CT were compared with the biopsied HER2 status and Δ-TLG by receiver operating characteristic analyses. Results: Trial biopsies were HER2-positive in 31 patients, HER2-negative in 6 patients, and borderline HER2-positive in 3 patients. The [68Ga]Ga-ABY-025 PET/CT cutoff SUVmax of 6.0 predicted a Δ-TLG lower than -25% with 86% sensitivity and 67% specificity in soft-tissue lesions (area under the curve, 0.74 [95% CI, 0.67-0.82]; P = 0.01). Compared with the HER2 status, this cutoff resulted in clinically relevant discordant findings in 12 of 40 patients. Metabolic response (Δ-TLG) was more pronounced in PBC (-71% [95% CI, -58% to -83%]; P < 0.0001) than in MBC (-27% [95% CI, -16% to -38%]; P < 0.0001), but [68Ga]Ga-ABY-025 SUVmax was similar in both with a mean SUVmax of 9.8 (95% CI, 6.3-13.3) and 13.9 (95% CI, 10.5-17.2), respectively (P = 0.10). In multivariate analysis, global Δ-TLG was positively associated with the number of previous treatments (P = 0.0004) and negatively associated with [68Ga]Ga-ABY-025 PET/CT SUVmax (P = 0.018) but not with HER2 status (P = 0.09). Conclusion: [68Ga]Ga-ABY-025 PET/CT predicted early metabolic response to HER2-targeted therapy in HER2-positive breast cancer. Metabolic response was attenuated in recurrent disease. [68Ga]Ga-ABY-025 PET/CT appears to provide an estimate of the HER2 expression required to induce tumor metabolic remission by targeted therapies and might be useful as an adjunct diagnostic tool.
引用
- Alhuseinalkhudhur A, Lindman H, Liss P, et al. Human Epidermal Growth Factor Receptor 2-Targeting [68Ga]Ga-ABY-025 PET/CT Predicts Early Metabolic Response in Metastatic Breast Cancer. J Nucl Med. 2023. PMID: 37442602. doi:10.2967/jnumed.122.265364
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。